Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female age ≥18 years~* Patient is scheduled to undego orthotopic liver transplantation (OLT)~* Patient has a natural MAYO End-Stage Liver Disease (MELD) score of 15-40~* Patient is willing to give voluntary written informed consent before any study- related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudicing future medical care~Exclusion Criteria:~* Patient has a history of severe hypersensitivity reaction to plasma-derived products or to any excipient of the investigational product~* Patient is known to be IgA deficient with documented antibodies against IgA~* Patient is a planned recipient for a living donor OLT~* Patient has a severe deficiency of Protein S~* Patient is currently participating in an interventional clinical study or has participated in one within 30 days of the date of their OLT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octaplas™ (Type: None): Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
- Plasma (Type: None): Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).

Based on this trial design, predict the completion outcome and termination type (if applicable).